Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
Over the last 12 months, insiders at Achieve Life Sciences, Inc. have bought $91,700 and sold $0 worth of Achieve Life Sciences, Inc. stock.
On average, over the past 5 years, insiders at Achieve Life Sciences, Inc. have bought $53,733 and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Bencich John (CEO) — $45,850. Stewart Richard Alistair (Executive Chairman) — $45,850.
The last purchase of 10,000 shares for transaction amount of $45,850 was made by Bencich John (CEO) on 2024‑03‑04.
2024-03-04 | CEO | 10,000 0.0492% | $4.58 | $45,850 | +4.04% | |||
2024-03-04 | Executive Chairman | 10,000 0.0492% | $4.58 | $45,850 | +4.04% | |||
2023-05-30 | CEO | 5,000 0.0246% | $5.50 | $27,500 | -26.44% | |||
2022-11-18 | CEO | 22,000 – | $0 | $0 | +107.53% | |||
2021-05-27 | CEO | 6,000 0.0716% | $7.00 | $42,000 | -3.40% | |||
2019-06-11 | Sale | 10 percent owner | 312,145 4.6633% | $3.11 | $972,288 | -71.03% | ||
2019-06-11 | 10 percent owner | 12,813 0.2335% | $3.80 | $48,689 | -71.03% | |||
2019-05-23 | Chairman & CEO | 17,500 0.2417% | $3.61 | $63,093 | -74.93% | |||
2016-08-19 | Sale | CFO | 2,760 0.0092% | $0.57 | $1,573 | -21.05% | ||
2016-06-13 | Sale | President and CEO | 9,712 0.032% | $1.03 | $9,959 | -50.96% | ||
2016-06-13 | Sale | EVP, CMO | 2,874 0.0095% | $1.03 | $2,947 | -50.96% | ||
2016-03-15 | Sale | President and CEO | 24,066 0.0807% | $0.83 | $19,975 | -30.12% | ||
2016-03-15 | Sale | EVP, CMO | 6,508 0.0218% | $0.83 | $5,402 | -30.12% | ||
2016-03-15 | Sale | CFO | 1,668 0.0056% | $0.83 | $1,384 | -30.12% | ||
2015-08-18 | Sale | CFO | 2,854 0.0103% | $2.76 | $7,877 | -62.45% | ||
2015-06-12 | Sale | President and CEO | 9,142 0.0381% | $2.69 | $24,592 | -56.36% | ||
2015-06-12 | Sale | EVP, CMO | 2,816 0.0117% | $2.69 | $7,575 | -56.36% | ||
2015-05-20 | Sale | President and CEO | 15,086 0.0639% | $1.88 | $28,362 | +11.11% | ||
2015-05-20 | Sale | EVP, CMO | 4,184 0.0177% | $1.88 | $7,866 | +11.11% | ||
2014-08-13 | Sale | President and CEO | 36,682 0.1682% | $3.17 | $116,282 | -30.49% |
Bencich John | CEO | 76724 0.2234% | $5.13 | 4 | 3 | <0.0001% |
Stewart Richard Alistair | Executive Chairman | 38501 0.1121% | $5.13 | 2 | 0 | <0.0001% |
COHEN STEVEN A/SAC CAPITAL MGMT LP | 10 percent owner | 1454752 4.2362% | $5.13 | 1 | 0 | |
S A C CAPITAL MANAGEMENT L L C | 10 percent owner | 1454752 4.2362% | $5.13 | 1 | 0 | |
SAC CAPITAL ADVISORS LLC | 10 percent owner | 1454752 4.2362% | $5.13 | 1 | 0 |
Franklin Templeton Investments | $17.19M | 17.37 | 5.96M | New | +$17.19M | 0.01 | |
Sofinnova | $6.9M | 4.42 | 1.52M | New | +$6.9M | 0.01 | |
The Vanguard Group | $4.31M | 2.76 | 948,441 | +56.58% | +$1.56M | <0.0001 | |
Altium Capital Management Lp | $3.8M | 2.43 | 835,470 | New | +$3.8M | 0.45 | |
Nantahala Capital Management Llc | $2.97M | 1.9 | 654,000 | New | +$2.97M | 0.14 |